Summit Therapeutics Inc. (SMMT)

NASDAQ: SMMT · Real-Time Price · USD

14.87

+0.91 (6.52%)

At close: Aug 10, 2026, 4:00 PM EDT

14.79

-0.08 (-0.54%)

Pre-market: Aug 11, 2026, 4:55 AM EDT

Summit Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	-306.11	-556.75	-60.21	-29.26	-26.74	-23.61
Research & Development	-568.74	-537.67	-135.77	461.44	-52	-85.35
Other Operating Expenses	-	-	-	-	-5.95	-20.97
Total Operating Expenses	-874.84	-1,094	-195.98	432.18	-84.69	-129.93
Operating Income	874.84	1,094	195.98	-432.18	-72.09	-86.19
Interest Expense	-	-	-8.69	-16.46	-4.4	-
Other Non-Operating Income (Expense)	-170.67	14.84	13.37	11.18	-2.29	-2.42
Total Non-Operating Income (Expense)	-170.67	14.84	4.68	-5.28	-6.69	-2.42
Pretax Income	704.18	1,109	200.67	-437.46	-78.78	-88.6
Net Income	-856.09	-1,080	-221.32	-614.93	-78.78	-88.6
Net Income to Common	-856.09	-1,080	-221.32	-614.93	-78.78	-88.6
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	766	748	719	620	193	132
Shares Outstanding (Diluted)	766	748	719	620	193	132
Shares Change	4.03%	4.06%	15.96%	220.50%	46.78%	89.45%
EPS (Basic)	-1.12	-1.44	-0.31	-0.99	-0.41	-0.67
EPS (Diluted)	-1.12	-1.44	-0.31	-0.99	-0.41	-0.67
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-459.82	-323.59	-142.25	-76.89	-42.21	-72.89
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.60	-0.43	-0.20	-0.12	-0.22	-0.55
EBITDA	875.02	1,095	196.07	-431.98	-70.83	-83.73
EBIT	874.84	1,094	195.98	-432.18	-72.09	-86.19

SEC Filings: 10-K · 10-Q